Clifford A. Brass

13.2k total citations · 4 hit papers
115 papers, 7.8k citations indexed

About

Clifford A. Brass is a scholar working on Hepatology, Epidemiology and Genetics. According to data from OpenAlex, Clifford A. Brass has authored 115 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Hepatology, 61 papers in Epidemiology and 18 papers in Genetics. Recurrent topics in Clifford A. Brass's work include Hepatitis C virus research (72 papers), Liver Disease Diagnosis and Treatment (44 papers) and Hepatitis B Virus Studies (31 papers). Clifford A. Brass is often cited by papers focused on Hepatitis C virus research (72 papers), Liver Disease Diagnosis and Treatment (44 papers) and Hepatitis B Virus Studies (31 papers). Clifford A. Brass collaborates with scholars based in United States, France and Germany. Clifford A. Brass's co-authors include Janice K. Albrecht, Bruce R. Bacon, Navdeep Boparai, Fred Poordad, Mark Sulkowski, Zachary Goodman, Ira M. Jacobson, Jonathan McCone, Eric Lawitz and Vilma Sniukiene and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

Clifford A. Brass

113 papers receiving 7.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

2011 1.9k citations Fred Poordad, Jonathan McCone et al. New England Journal of Medicine profile →
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

2011 1.2k citations Bruce R. Bacon, Stuart C. Gordon et al. New England Journal of Medicine profile →
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

2009 889 citations John G. McHutchison, Eric Lawitz et al. New England Journal of Medicine profile →
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

2010 515 citations Paul Y. Kwo, Eric Lawitz et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Clifford A. Brass United States	34	7.0k	6.1k	1.3k	670	550	115	7.8k
Thomas Urban United States	31	3.3k 0.5×	2.7k 0.4×	505 0.4×	652 1.0×	907 1.6×	65	5.9k
Jeanne G. Waggoner United States	33	3.9k 0.6×	3.6k 0.6×	335 0.3×	499 0.7×	495 0.9×	58	5.2k
Thomas S. Chen United States	14	2.7k 0.4×	2.7k 0.4×	142 0.1×	343 0.5×	746 1.4×	21	4.3k
Javier Salmerón Spain	26	1.8k 0.3×	1.8k 0.3×	179 0.1×	212 0.3×	401 0.7×	80	3.2k
John Alam United States	19	1.9k 0.3×	1.6k 0.3×	540 0.4×	364 0.5×	323 0.6×	37	2.8k
Julie R. Jonsson Australia	28	2.1k 0.3×	2.6k 0.4×	69 0.1×	181 0.3×	432 0.8×	54	3.9k
Lai Wei China	28	1.8k 0.3×	1.9k 0.3×	325 0.3×	89 0.1×	351 0.6×	164	2.8k
Jaw‐Ching Wu Taiwan	36	2.7k 0.4×	2.7k 0.4×	192 0.2×	54 0.1×	1.1k 2.0×	102	4.8k
Gunda Millonig Germany	28	1.1k 0.2×	1.5k 0.2×	145 0.1×	132 0.2×	640 1.2×	74	3.2k
P. J. Scheuer United Kingdom	22	2.0k 0.3×	2.0k 0.3×	96 0.1×	131 0.2×	260 0.5×	46	3.2k

Countries citing papers authored by Clifford A. Brass

Since Specialization

Citations

This map shows the geographic impact of Clifford A. Brass's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clifford A. Brass with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clifford A. Brass more than expected).

Fields of papers citing papers by Clifford A. Brass

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clifford A. Brass. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clifford A. Brass. The network helps show where Clifford A. Brass may publish in the future.

Co-authorship network of co-authors of Clifford A. Brass

This figure shows the co-authorship network connecting the top 25 collaborators of Clifford A. Brass. A scholar is included among the top collaborators of Clifford A. Brass based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clifford A. Brass. Clifford A. Brass is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rasmussen, Daniel Guldager Kring, Quentin M. Anstee, Richard Torstenson, et al.. (2022). NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned. Journal of Hepatology. 78(4). 852–865. 20 indexed citations

Breckons, Matthew, Yemi Oluboyede, Luke Vale, et al.. (2020). Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis. JHEP Reports. 2(3). 100099–100099. 36 indexed citations

Chatterji, Udayan, Jose A. Garcia-Rivera, Katarzyna Gawlik, et al.. (2014). The Combination of Alisporivir plus an NS5A Inhibitor Provides Additive to Synergistic Anti-Hepatitis C Virus Activity without Detectable Cross-Resistance. Antimicrobial Agents and Chemotherapy. 58(6). 3327–3334. 34 indexed citations

Melia, Michael T., Norbert Bräu, Fred Poordad, et al.. (2014). Infections During Peginterferon/Ribavirin Therapy Are Associated With the Magnitude of Decline in Absolute Lymphocyte Count: Results of the IDEAL Study. Clinical Infectious Diseases. 58(7). 960–969. 8 indexed citations

Gordon, Stuart C., Eric M. Yoshida, Eric Lawitz, et al.. (2013). Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa‐2b/ribavirin. Alimentary Pharmacology & Therapeutics. 38(1). 16–27. 17 indexed citations

Barnard, Richard J. O., John A. Howe, Robert A. Ogert, et al.. (2013). Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology. 444(1-2). 329–336. 54 indexed citations

Sulkowski, Mark S., Fred Poordad, M.P. Manns, et al.. (2012). Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology. 57(3). 974–984. 52 indexed citations

Jacobson, Ira M., Patrick Marcellin, Stefan Zeuzem, et al.. (2012). Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology. 56(2). 567–575. 47 indexed citations

Clark, Paul J., Alexander Thompson, Stuart C. Gordon, et al.. (2011). PREDICTORS OF CONSENT TO PHARMACOGENOMICS TESTING IN THE IDEAL STUDY. Hepatology. 54.

10.

Zeuzem, Stefan, John M. Vierling, Rafael Esteban, et al.. (2011). 484 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN. Journal of Hepatology. 54. S198–S199. 30 indexed citations

11.

Brass, Clifford A., Richard J. O. Barnard, John A. Howe, et al.. (2011). 1194 SUSTAINED VIROLOGIC RESPONSE AND BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS OBSERVED IN PATIENTS INFECTED WITH HCV GENOTPYPE 1A/1B WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN. Journal of Hepatology. 54. S471–S472. 9 indexed citations

12.

Thompson, Alexander, Paul J. Clark, David M. Vock, et al.. (2011). PREDICTING PEGINTERFERON-alpha AND RIBAVIRIN TREATMENT RESPONSE IN GENOTYPE 1 HCV PATIENTS - SIMPLE NOMOGRAMS TO SUPPORT CLINICIANS. Hepatology. 54. 95–8. 1 indexed citations

13.

Thompson, Alexander, Paul J. Clark, Hans L. Tillmann, et al.. (2011). Il28B C/c Genotype Is Predictive of >= 1 Log10 Iu/ml Reduction in Plasma Hcv Rna After 4 Weeks of Peginterferon (Pegifn) and Ribavirin (Rbv) Therapy: Implications for the Use of the Lead-In Strategy for Direct-Acting Antiviral-Based Treatment Regimens. Hepatology. 54. 3 indexed citations

14.

Bacon, Bruce R., Stuart C. Gordon, Eric Lawitz, et al.. (2011). Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection. New England Journal of Medicine. 364(13). 1207–1217. 1229 indexed citations breakdown →

15.

Kwo, Paul Y., Eric Lawitz, Jonathan McCone, et al.. (2010). Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. The Lancet. 376(9742). 705–716. 515 indexed citations breakdown →

16.

Sulkowski, Mark, Mitchell L. Shiffman, Nezam H. Afdhal, et al.. (2010). Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate. Gastroenterology. 139(5). 1602–1611.e1. 82 indexed citations

17.

Sulkowski, Mark, M. Shiffman, Jonathan McCone, et al.. (2009). 126 HEMOGLOBIN DECLINE IS ASSOCIATED WITH SVR AMONG HCV GENOTYPE 1-INFECTED PERSONS TREATED WITH PEGINTERFERON (PEG)/RIBAVIRIN (RBV): ANALYSIS FROM THE IDEAL STUDY. Journal of Hepatology. 50. S51–S52. 3 indexed citations

18.

Zeuzem, Stefan, Yves Horsmans, Rafael Esteban, et al.. (2005). Efficacy of 6 months treatment with PEG-interferon alpha-2b plus ribavirin (P/R) in patients infected with hepatitis C with genotype 1 of low viral load (G1LVL). Journal of Hepatology. 42. 229. 5 indexed citations

19.

Brass, Clifford A.. (1998). Efficacy of interferon monotherapy in the treatment of relapsers and nonresponders with chronic hepatitis C infection. Clinical Therapeutics. 20(3). 388–397. 5 indexed citations

20.

Brass, Clifford A., et al.. (1994). Increased oxyradical production during reoxygenation of perfused rat liver. Signal versus injury.. PubMed. 58(12). 1329–35. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact